Brief: Catalyst Biosciences Inc Says As A Result Of Reduction In Headcount, Estimates Co Will Incur Up To About $0.8 Million In Costs In Q2 Of 2022
05/04/2022 11:07
April 5 (Reuters) - Catalyst Biosciences Inc CBIO.O :
* CATALYST BIOSCIENCES INC - AS A RESULT OF REDUCTION IN
HEADCOUNT, ESTIMATES CO WILL INCUR UP TO ABOUT $0.8 MILLION IN
COSTS IN Q2 OF 2022
Source: [ID: https://bit.ly/3r4bfec]
Further company coverage: CBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gyre Therapeutics
See all newsBrief: Gyre Therapeutics - Enters Employment Agreement With Ying Luo As CEO - SEC Filing
Gyre Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Gyre Therapeutics, Inc. expected to post a loss of 13 cents a share - Earnings Preview
Brief: Gyre Therapeutics Reports Second Quarter 2026
Gyre Therapeutics Q2 revenue beats estimates on higher ETUARY sales volumes